

Amendments to the Claims:


This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

What is claimed is:

1-34. (Cancelled)

35. (New) A compound of formula I



or a stereoisomeric form of a compound of formula I or a physiologically tolerable salt of a compound of formula I,

wherein B₆, B₇, B₈ and B₉ are ring atoms independently chosen from carbon atoms and nitrogen atoms and wherein B₆, B₇, B₈ and B₉ together are no more than two nitrogen atoms at the same time;

where the substituents R¹, R², R³, R⁴ and R⁸ may be independently chosen from

1. hydrogen atom,
2. halogen,
3. -OH,
4. -CN,
5. sulfo,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

6. -NO₂,
7. -NH₂,
8. alkoxy,
9. substituted amino,
10. -NH-C(O)-R¹⁵, wherein R¹⁵ is a heterocycle having 5 to 7 ring atoms, an alkyl, an aryl, a substituted aryl or a substituted alkyl,
11. -COOH,
12. -O-R¹⁰, wherein R¹⁰ is alkyl, substituted alkyl or aryl,
13. -C(O)-R¹², wherein R¹² is alkyl, substituted alkyl or aryl,
14. -C(O)-O-R¹², wherein R¹² is alkyl, substituted alkyl or aryl,
15. aryl,
16. -O-aryl,
17. substituted aryl,
18. -O-substituted aryl,
19. alkyl,
20. substituted alkyl,
21. -CF₃ or
22. -CF₂-CF₃,

provided that at least one of R¹, R², R³, R⁴ and R⁸ is not a hydrogen atom,

- R⁵ is
1. hydrogen atom,
 2. alkyl,
 3. alkyl radical, substituted at one or more positions by one or more of the radicals, halogen, amino or hydroxyl,
 4. -C(O)-R⁹ or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

5. $-S(O)_2-R^9$, in which

- R^9 is
- alkyl,
 - alkyl radical, substituted at one or more positions by one or more of the radicals, halogen, amino or hydroxyl,
 - aryl,
 - aryl radical, substituted at one or more positions by one or more of the radicals, halogen, amino, or hydroxyl,
 - $-NH_2$,
 - alkoxy or
 - substituted amino, and

R^6 and R^7 may be independently chosen from

- hydrogen atom,
- halogen,
- $-OH$,
- methyl,
- $-O-(C_1-C_{10})$ -alkyl, wherein alkyl is unsubstituted or mono- to tri- substituted by substituents independently chosen from

- aryl,
- halogen,
- $-NO_2$,
- sulfo,
- $-COOH$,
- $-NH_2$,
- $-O-(C_1-C_4)$ -alkyl or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

5.8 -OH, or

6. $-N(R^{13})_2$, wherein R^{13} is independently of one another chosen from hydrogen atom, aryl, $-C(O)-(C_1-C_4)$ -alkyl or substituted aryl or alkyl, wherein said $-C(O)-(C_1-C_4)$ -alkyl is unsubstituted or mono- or tri- substituted independently of one another as defined under 5.1 to 5.8, or R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms.

36. (New) A compound of formula I as claimed in claim 35,
wherein

B_6 , B_7 , B_8 , and B_9 are each a carbon atom,

R^1 , R^2 , R^3 , R^4 and R^8 are independently chosen from

1. hydrogen atom,
2. halogen,
3. -CN,
4. -COOH,
5. -NO₂,
6. -NH₂,
7. -O-(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from
 - 7.1 phenyl, which is unsubstituted or mono- to penta- substituted by substituents independently chosen from halogen or -O-(C₁-C₄)-alkyl,
 - 7.2 halogen,
 - 7.3 -NH₂,

- 7.4 -OH,
- 7.5 -COOR¹⁶, wherein R¹⁶ is hydrogen atom or -(C₁-C₁₀)-alkyl,
- 7.6 -NO₂,
- 7.7 -S(O)_y-R¹⁴, wherein y is zero, 1 or 2, R¹⁴ is -(C₁-C₁₀)-alkyl, phenyl, amino, or N(R¹³)₂, wherein the phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from
- 7.7.1 phenyl, which is unsubstituted or mono- to penta- substituted by substituents independently chosen from halogen or -O-(C₁-C₄)-alkyl,
- 7.7.2 halogen,
- 7.7.3 -NH₂,
- 7.7.4 -OH,
- 7.7.5 -COOR¹⁶, wherein R¹⁶ is hydrogen atom or -(C₁-C₁₀)-alkyl,
- 7.7.6 -NO₂;
- 7.7.7 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine;
- 7.7.8 -(C₃-C₇)-cycloalkyl;
- 7.7.9 =O;
- 7.7.10 -S(O)_y-R^{14A}, wherein y is as defined above in 7.7 and R^{14A} is -(C₁-C₁₀)-alkyl, phenyl, amino, or N(R¹³)₂, wherein

the phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from 7.7.1 to 7.7.9 or another -O-phenyl having its phenyl group either unsubstituted or substituted by substituents independently chosen from those as defined under 7.7.1 to 7.7.9, or

7.7.11 -O-phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.7.1 to 7.7.10 or another -O-phenyl having its phenyl group either unsubstituted or substituted by substituents independently chosen from those as defined under 7.7.1 to 7.7.10,

and further wherein for the $N(R^{13})_2$ substituent in paragraphs 7.7 and 7.7.10, R^{13} is independently of one another chosen from hydrogen atom, phenyl, $-(C_1-C_{10})$ -alkyl, $-C(O)-(C_1-C_7)$ -alkyl, $-C(O)$ -phenyl, $-C(O)-NH-(C_1-C_7)$ -alkyl, $-C(O)-O$ -phenyl, $-C(O)-NH$ -phenyl, $-C(O)-O-(C_1-C_7)$ -alkyl, $-S(O)_y-R^{14A}$, wherein R^{14A} and y are as defined above, and wherein the R^{13} alkyl or phenyl groups in each case are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.7.1 to 7.7.11, or R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

7.8 -O-phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from

- 7.8.1 those as defined under 7.1 to 7.7,
- 7.8.2 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine;
- 7.8.3 $-(C_3-C_7)$ -cycloalkyl
- 7.8.4 $=O$
- 7.8.5 $-O$ -phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.7.1 to 7.7.11,
- 7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
- 7.10 $-(C_3-C_7)$ -cycloalkyl or
- 7.11 $=O$,
- 8. $-N(R^{13})_2$, wherein R^{13} is as defined in 7.7,
- 9. $-NH-C(O)-R^{15}$, wherein R^{15} is
 - 9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,

wherein said radical is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11, -CF₃, benzyl or by -(C₁-C₁₀)-alkyl, wherein alkyl is mono to tri-substituted independently of one another as defined under 7.1 to 7.11,

- 9.2 -(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 or by -O-(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11,
- 9.3 -(C₃-C₇)-cycloalkyl,
- 9.4 -N(R¹³)₂, wherein R¹³ is as defined in 7.7, or
- 9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11, by -O-(C₁-C₁₀)-alkyl, by -CN, by -CF₃, by -(C₁-C₁₀)-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 7.1 to 7.11, or by two substituents of the phenyl radical which form a dioxolan ring,
- 9.6 a radical selected from morpholine and pyridine wherein said radical is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11, -CF₃, benzyl or by -(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono to tri- substituted independently of one another as defined under 7.1 to 7.11,

10. -S(O)y-R¹⁴, wherein R¹⁴ and y are as defined in 7.7,

11. -C(O)-R^{12} , wherein R^{12} is phenyl or $\text{-(C}_1\text{-C}_7\text{)-alkyl}$, wherein phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11,
12. -C(O)-O-R^{12} , wherein R^{12} is phenyl or $\text{-(C}_1\text{-C}_7\text{)-alkyl}$, wherein phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11,
13. $\text{-(C}_1\text{-C}_{10}\text{)-alkyl}$, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11,
14. $\text{-O-(C}_1\text{-C}_6\text{)-alkyl-O-(C}_1\text{-C}_6\text{)-alkyl}$,
15. $\text{-O-(C}_0\text{-C}_4\text{)-alkyl-(C}_3\text{-C}_7\text{)-cycloalkyl}$,
16. $\text{-(C}_1\text{-C}_4\text{)-alkyl-N(R}^{13}\text{)}_2$, wherein R^{13} is as defined in 7.7
17. -CF_3 or
18. $\text{-CF}_2\text{-CF}_3$,

provided that at least one of R^1 , R^2 , R^3 , R^4 and R^8 is not a hydrogen atom,

- R^5 is
1. hydrogen atom,
 2. $\text{-(C}_1\text{-C}_{10}\text{)-alkyl}$, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.4,
 3. -C(O)-R^9 , wherein R^9 is
 -NH_2 , $\text{-(C}_1\text{-C}_{10}\text{)-alkyl}$, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.4, or $\text{-N(R}^{13}\text{)}_2$, wherein R^{13} is as defined in 7.7,
or
 4. $\text{-S(O)}_2\text{-R}^9$, wherein R^9 is as defined in 3 immediately above,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

or R⁴ and R⁵ together with the atom to which they are bonded form a heterocycle,
or R³ and R⁵ together with the atom to which they are bonded form a heterocycle containing
an additional oxygen atom in the ring and
R⁶ and R⁷ independently of one another are chosen from hydrogen atom or methyl.

37. (New) A compound as claimed in claim 36,
wherein

B₆, B₇, B₈, and B₉ are each a carbon atom,

R¹, R², R³ and R⁴ independently of one another are hydrogen atom, halogen,
cyano, nitro, amino, -O-(C₁-C₇)-alkyl, phenyl, -O-phenyl, -CF₂-CF₃,
-CF₃, N(R¹³)₂,

wherein R¹³ is independently of one another chosen from hydrogen atom,
-(C₁-C₇)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl,
-C(O)-O-phenyl, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-(C₁-C₇)-alkyl or -(C₁-C₁₀)-alkyl,
wherein alkyl, pyridyl or phenyl are unsubstituted or mono- to tri- substituted
by substituents independently chosen from those as defined under 7.1 to
7.11, or R¹³ together with nitrogen atom to which it is bonded form a
heterocycle having 5 to 7 ring atoms,

-S(O)_y-R¹⁴,

wherein y is zero, 1 or 2, and R¹⁴ is -(C₁-C₁₀)-alkyl, phenyl,
which phenyl is unsubstituted or mono- to penta- substituted as
defined for substituents under 7.1 to 7.11, amino or -N(R¹³)₂,

wherein R¹³ is independently of one another chosen from hydrogen
atom, -(C₁-C₇)-alkyl-C(O)-(C₁-C₇)-alkyl, -C(O)-phenyl, C(O)-pyridyl,

-C(O)-NH-(C₁-C₄)-alkyl, -C(O)-O-phenyl, -C(O)-O-(C₁-C₄)-alkyl or
-(C₁-C₁₀)-alkyl, wherein each alkyl is unsubstituted or mono- to tri-
substituted independently of one another as defined under 7.1 to 7.11,
or R¹³ together with nitrogen atom to which it is bonded form a
heterocycle having 5 to 7 ring atoms, or

-C(O)-O-R¹², wherein R¹² is phenyl or -(C₁-C₇)-alkyl, wherein said phenyl or alkyl are
unsubstituted or mono- to penta- substituted by substituents independently chosen
from those as defined under 7.1 to 7.11,

R⁶, R⁷ and R⁸ independently of one another are hydrogen atom, methyl, amino, -N(R¹³)₂,
wherein R¹³ is independently of one another chosen from

hydrogen atom, -(C₁-C₇)-alkyl-C(O)-(C₁-C₇)-alkyl, -C(O)-phenyl,

C(O)-pyridyl, -C(O)-NH-(C₁-C₄)-alkyl, -C(O)-O-phenyl,

-C(O)-O-(C₁-C₄)-alkyl or -(C₁-C₁₀)-alkyl, wherein pyridyl, alkyl or phenyl

are unsubstituted or mono- to tri- substituted independently of

one another as defined under 7.1 to 7.11, or

R¹³ together with nitrogen atom to which it is bonded form


a heterocycle having 5 to 7 ring atoms,

provided that at least one of R¹, R², R³, R⁴ and R⁸ is not a hydrogen atom.

38. (New) A compound of formula II,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



or a stereoisomeric form of a compound of the formula II, or a physiologically tolerable salt of a compound of the formula II,

wherein, R^1 , R^2 and R^3 are independently chosen from hydrogen atom, halogen, cyano,

amino, $-O-(C_1-C_4)\text{-alkyl}$, nitro, $-CF_3$, $-CF_2-CF_3$, $-S(O)_y-R^{14}$,

wherein y is 1 or 2,

R^{14} is amino, $-(C_1-C_7)\text{-alkyl}$, phenyl, which is unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 7.1 to 7.9 of claim 36, or $-N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom,

$-(C_1-C_7)\text{-alkyl-C(O)-(C}_1\text{-C}_7\text{-alkyl)}$, $-C(O)\text{-phenyl}$, $-C(O)\text{-O-phenyl}$,

$-C(O)\text{-pyridyl}$, $-C(O)\text{-NH-(C}_1\text{-C}_4\text{-alkyl)}$, $-C(O)\text{-O-(C}_1\text{-C}_4\text{-alkyl)}$, or

$-(C_1-C_{10})\text{-alkyl}$, wherein pyridyl, alkyl or phenyl are unsubstituted or

mono- to tri- substituted with substituents independently chosen from

those as defined under 7.1 to 7.11 of claim 36, or R^{13} together with the

nitrogen atom to which it is bonded form a heterocycle having 5 to

7 ring atoms,

provided that at least one of R^1 , R^2 and R^3 is not a hydrogen atom, and

R^5 is hydrogen atom, $-(C_1-C_{10})\text{-alkyl}$,


wherein alkyl is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 7.1 to 7.4 of claim 36, $-C(O)-R^9$ or $-S(O)_2-R^9$, wherein

R^9 is $-(C_1-C_{10})$ -alkyl, $-O-(C_1-C_{10})$ -alkyl,

wherein alkyl is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 7.1 to 7.4 of claim 36, phenyl, which is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 7.1 to 7.11 of claim 36, or $-N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, $-(C_1-C_7)$ -alkyl- $C(O)-(C_1-C_7)$ -alkyl, $-C(O)$ -phenyl, $-C(O)$ -O-phenyl, $-C(O)$ -pyridyl, $-C(O)$ -NH- (C_1-C_4) -alkyl, $-C(O)$ -O- (C_1-C_4) -alkyl, or $-(C_1-C_{10})$ -alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri- substituted with substituents independently chosen from those as defined under 7.1 to 7.11 of claim 36, or R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms.

39. (New) A compound of formula II,



or a stereoisomeric form of a compound of the formula II, or a physiologically tolerable salt of a compound of the formula II,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

wherein R^1 , R^2 and R^3 are independently chosen from hydrogen atom, halogen, cyano, amino, $-O-(C_1-C_4)$ -alkyl, nitro, $-CF_3$ or $N(R^{13})_2$,
wherein R^{13} is independently of one another chosen from hydrogen atom, $-(C_1-C_7)$ -alkyl, $-C(O)-(C_1-C_7)$ -alkyl, $-C(O)$ -pyridyl, $-C(O)$ -phenyl or $-C(O)-O-(C_1-C_4)$ -alkyl, wherein alkyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from halogen or $-O-(C_1-C_4)$ -alkyl, and
 R^5 is hydrogen atom, $-C(O)-CH_3$ -, methyl, $-S(O)_2-CH_3$, $-C(O)$ -morpholinyl, $-CH_2-CH_2-OH$ or $-CH_2-C(O)-NH_2$,
provided that no more than two of R^1 , R^2 , R^3 and R^5 are a hydrogen atom.

40. (New) A compound as claimed in claim 39, wherein

R^1 is bromo, $-CF_3$ or chloro, R^2 is hydrogen atom or $O-(C_1-C_2)$ -alkyl, R^3 is hydrogen atom, bromo, chloro or $-N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, $-C(O)$ -phenyl, $-(C_1-C_7)$ -alkyl, $-C(O)-(C_1-C_4)$ -alkyl or $-C(O)-O-(C_1-C_4)$ -alkyl, wherein alkyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from halogen or $-O-(C_1-C_2)$ -alkyl, and

R^5 is hydrogen atom, $-C(O)-CH_3$ -, methyl or $-S(O)_2-CH_3$,

provided that no more than two of R^1 , R^2 , R^3 and R^5 are a hydrogen atom.


41. (New) A compound as claimed in claim 39, wherein

R^1 and R^3 are each chloro, R^2 is $-C(O)-CH_3$ and R^5 is hydrogen atom, or


R^1 and R^3 are each chloro, R^2 is $-C(O)-CH_2-CH_3$ and R^5 is hydrogen atom.

42. (New) A process for the preparation of a compound of the formula I as claimed in claim 35, which comprises


reacting a compound of formula III




in which R¹, R², R³, R⁴, B₆, B₇, B₈ and B₉ are each as defined in formula I, with a compound of the formula IV,




in the presence of an acid, to yield a compound of the formula V



which is reacted with hydrazine hydrate and later with R⁶CHO or formaldehyde (R⁶ is H) to give a compound of formula VI




and then oxidizing the compound of formula VI to give a compound of the formula VII,



where R^1 to R^4 , R^6 to R^8 and B_6 to B_9 are as defined in formula I, to give a compound of formula I.

43. (New) A process according to claim 42, wherein a compound of the formula VII is reacted with a compound of the formula VIII



where Y is halogen or $-OH$ and R^5 is as defined in formula I, to give a compound of the formula I.

44. (New) A process according to claim 42, which further comprises resolving a compound of the formula I formed by the process of claim 42, which on account of its

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

chemical structure occurs in enantiomeric forms, into the pure enantiomers by salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases or derivatization by means of chiral enantiomerically pure compounds, separation of the diastereomers thus obtained, and removal of the chiral auxiliary groups.

45. (New) The process according to claim 44, wherein the chiral enantiomerically pure compounds are amino acids.

46. (New) A process according to claim 43, which further comprises resolving a compound of the formula I formed by the process of claim 43, which on account of its chemical structure occurs in enantiomeric forms, into the pure enantiomers by salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases or derivatization by means of chiral enantiomerically pure, separation of the diastereomers thus obtained, and removal of the chiral auxiliary groups.

47. (New) The process according to claim 46, wherein the chiral enantiomerically pure compounds are amino acids.

48. (New) A process according to claim 42, which further comprises isolating a compound of the formula I prepared by the process of claim 42, either in free form or, in the case of the presence of acidic or basic groups, converting it into a physiologically tolerable salt.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

49. (New) A process according to claim 43, which further comprises isolating a compound of the formula I prepared by the process of claim 43, either in free form or, in the case of the presence of acidic or basic groups, converting it into a physiologically tolerable salt.

50. (New) A process according to claim 44, which further comprises isolating a compound of the formula I prepared by process 44, either in free form or, in the case of the presence of acidic or basic groups, converting it into a physiologically tolerable salt.

51. (New) A composition which comprises an efficacious amount of at least one compound chosen from the compounds of formula I as claimed in claim 35, a physiologically tolerable salt of the compounds of the formula I or an optionally stereoisomeric form of the compounds of the formula I, together with at least one pharmaceutically suitable and physiologically tolerable excipient, additive, active compound or auxiliary.

52. (New) A method for treating a patient experiencing at least one disorder involving an increased activity of I κ B kinase, the method comprising administering to the patient an efficacious amount of at least one compound chosen from a compound of formula I as set forth in claim 35, a stereoisomeric form of a compound of the formula I, or a physiologically tolerable salt of a compound of the formula I.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

53. (New) The method as claimed in claim 52, wherein the at least one disorder is joint inflammation, acute synovitis, tuberculosis, atherosclerosis, muscle degeneration, cachexia, Reiter's syndrome, endotoxaemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, gout, toxic shock syndrome, chronic pulmonary inflammatory diseases, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, carcinoses, leukemia, sarcomas, lymph node tumors, skin carcinoses, lymphoma, apoptosis, graft versus host reaction, allograft rejection, leprosy, infections, acquired immune deficiency syndrome (AIDS); AIDS related complex, cachexia secondary to infection or malignancy; cachexia secondary to acquired immune deficiency syndrome or to cancer; keloid and scar tissue formation; pyresis; diabetes; inflammatory bowel diseases; diseases of or injury to the brain in which over-expression of $TNF\alpha$ has been implicated, psoriasis, Alzheimer's disease, carcinomatous disorders, cardiac infarct, chronic obstructive pulmonary disease and acute respiratory distress syndrome.

54. (New) The method of claim 53, wherein the disorder is a carcinomatous disorder and the at least one compound effects potentiation of the cytotoxic therapies used to treat the carcinomatous disorder.

55. (New) The method as claimed in claim 52, wherein the disorder is a joint inflammation disorder chosen from arthritis and arthritic conditions.


56. (New) The method as claimed in claim 55, wherein the disorder is arthritis or arthritic conditions chosen from rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, and osteoarthritis.

57. (New) The method of claim 52, wherein the disorder is chronic pulmonary inflammatory diseases chosen from asthma and adult respiratory distress syndrome.
58. (New) The method of claim 52, wherein the disorder is an infection chosen from viral infections, parasitic infections, and yeast and fungal infections.
59. (New) The method of claim 58, wherein the disorder is a viral infection chosen from HIV, cytomegalovirus, influenza, adenovirus and the Herpes group of viruses.
60. (New) The method of claim 52, wherein the disorder is malaria.
61. (New) The method of claim 60, wherein the malaria is cerebral malaria.
62. (New) The method of claim 52, wherein the disorder is a yeast infection, fungal infection, or fever and myalgias due to infection.
63. (New) The method of claim 62, wherein the fungal infection is fungal meningitis.
64. (New) The method of claim 52, wherein the disorder is an inflammatory bowel disease chosen from Crohn's disease and ulcerative colitis.
65. (New) The method of claim 52, wherein the disorder is a disease of or injury to the brain chosen from multiple sclerosis or head trauma.

66. (New) A method for treating a patient experiencing at least one disorder, the method comprising administering to the patient an efficacious amount of at least one compound chosen from a compound of formula II as set forth in claim 38, a stereoisomeric form of a compound of the formula II, or a physiologically tolerable salt of a compound of the formula II, wherein the at least one disorder is chosen from asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, carcinomatous disorders and cardiac infarct.

67. (New) A method for the production of a pharmaceutical for the prophylaxis or therapy of disorders in whose course an increased activity of I_kB kinase is involved, comprising

bringing into a suitable administration form at least one compound chosen from a compound of formula I,



or a stereoisomeric form of a compound of the formula I or a physiologically tolerable salt of a compound of the formula I, together with a pharmaceutically suitable and physiologically tolerable excipient,

where B₆, B₇, B₈ and B₉ are ring atoms independently chosen from carbon atoms and nitrogen atoms, where B₆, B₇, B₈ and B₉ together comprise no more than two nitrogen atoms; wherein

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

in case a)

the substituents R^1 , R^2 and R^3 may be independently chosen from:

- 1.1. hydrogen atom,
- 1.2. halogen,
- 1.3. -CN,
- 1.4. -COOH,
- 1.5. -NO₂,
- 1.6. -NH₂,
- 1.7. -O-(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta-

substituted by substituents independently chosen from:

- 1.7.1 phenyl, which is unsubstituted or mono- to penta- substituted by
substituents independently chosen from halogen or -O-(C₁-C₄)-alkyl,
- 1.7.2 halogen,
- 1.7.3 -NH₂,
- 1.7.4 -OH,
- 1.7.5 -COOR¹⁶, wherein R¹⁶ is hydrogen atom or -(C₁-C₁₀)-alkyl,
- 1.7.6 -NO₂,
- 1.7.7 -S(O)_y-R¹⁴, wherein y is zero, 1 or 2, R¹⁴ is -(C₁-C₁₀)-alkyl, phenyl,
amino, or N(R¹³)₂, wherein the phenyl is unsubstituted or mono- to
penta- substituted by substituents independently chosen from

- 1.7.7.1 phenyl, which is unsubstituted or mono- to penta-
substituted by substituents independently chosen from
halogen or -O-(C₁-C₄)-alkyl,

- 1.7.7.2 halogen,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

- 1.7.7.3 -NH₂,
- 1.7.7.4 -OH,
- 1.7.7.5 -COOR¹⁶, wherein R¹⁶ is hydrogen atom or -(C₁-C₁₀)-alkyl,
- 1.7.7.6 -NO₂;
- 1.7.7.7 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine;
- 1.7.7.8 -(C₃-C₇)-cycloalkyl;
- 1.7.7.9 =O;
- 1.7.7.10 -S(O)_y-R^{14A}, wherein y is as defined above in 1.7.7 and R^{14A} is -(C₁-C₁₀)-alkyl, phenyl, amino, or N(R¹³)₂, wherein the phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from 1.7.7.1 to 1.7.7.9 or another -O-phenyl having its phenyl group either unsubstituted or substituted by substituents independently chosen from those as defined under 1.7.7.1 to 1.7.7.9, or
- 1.7.7.11 -O-phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under

1.7.7.1 to 1.7.7.10 or another -O-phenyl having its phenyl group either unsubstituted or substituted by substituents independently chosen from those as defined under 1.7.7.1 to 1.7.7.10,

and further wherein for the $N(R^{13})_2$ substituent in paragraphs 1.7.7 and 1.7.7.10, R^{13} is independently of one another chosen from hydrogen atom, phenyl, $-(C_1-C_{10})$ -alkyl, $-C(O)-(C_1-C_7)$ -alkyl, $-C(O)$ -phenyl, $-C(O)-NH-(C_1-C_7)$ -alkyl, $-C(O)-O$ -phenyl, $-C(O)-NH$ -phenyl, $-C(O)-O-(C_1-C_7)$ -alkyl, $-S(O)_y-R^{14A}$, wherein R^{14A} and y are as defined above in paragraphs 1.7.7.10 and 1.7.7, respectively,

and wherein the R^{13} alkyl or phenyl groups in each case are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.7.1 to 1.7.7.11, or

R^{13} together with the nitrogen atom to which it is bonded is independently chosen to form a heterocycle having 5 to 7 ring atoms,

1.7.8 -O-phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from

1.7.8.1 those as defined under 1.7.1 to 1.7.7,

1.7.8.2 a radical selected from pyrrolidine,

tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine,

2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene
or thiomorpholine;

1.7.8.3 $-(C_3-C_7)\text{-cycloalkyl}$

1.7.8.4 $=O$

1.7.8.5 $-O\text{-phenyl}$, wherein phenyl is unsubstituted or
mono- to penta- substituted by substituents
independently chosen from those as defined under
1.7.7.1 to 1.7.7.11,

1.7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine,
piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine,
pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline,
isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,

1.7.10 $-(C_3-C_7)\text{-cycloalkyl}$ or

1.7.11 $=O$,

1.8. $-N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7,

1.9. $-NH-C(O)-R^{15}$, wherein R^{15} is

1.9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine,
piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine,
pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline,
isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
wherein said radical is unsubstituted or mono- to penta- substituted by
substituents independently chosen from those as defined under 1.7.1
to 1.7.11, by $-CF_3$, by benzyl or by $-(C_1-C_{10})\text{-alkyl}$, wherein the

- (C₁-C₁₀)-alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
- 1.9.2 -(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 or by -O-(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
- 1.9.3 -(C₃-C₇)-cycloalkyl,
- 1.9.4 -N(R¹³)₂, wherein R¹³ is as defined in 1.7.7 above, or
- 1.9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, by -O-(C₁-C₁₀)-alkyl, by -CN, by -CF₃, by -(C₁-C₁₀)-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or by two substituents of said phenyl which form a dioxolan ring,
- 1.10. -S(O)_y-R¹⁴, wherein R¹⁴ and y are as defined in 1.7.7,
- 1.11. -C(O)-R¹², wherein R¹² is phenyl or -(C₁-C₇)-alkyl, wherein alkyl or phenyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
- 1.12. -C(O)-O-R¹², wherein R¹² is as defined in 1.11,
- 1.13. -(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
- 1.14. -O-(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl,

- 1.15. $-\text{O}-(\text{C}_0-\text{C}_4)\text{-alkyl}-(\text{C}_3-\text{C}_7)\text{-cycloalkyl}$,
- 1.16. $-(\text{C}_1-\text{C}_4)\text{-alkyl-N}(\text{R}^{13})_2$, wherein R^{13} is as defined in 1.7.7 above
- 1.17. $-\text{CF}_3$ or
- 1.18. $-\text{CF}_2\text{-CF}_3$,

- R^4 is
- 1. $-(\text{C}_1-\text{C}_{10})\text{-alkyl}$, wherein alkyl is mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.10,
 - 2. $-\text{CF}_3$,
 - 3. $-\text{CF}_2\text{-CF}_3$,
 - 4. $-\text{CN}$,
 - 5. $-\text{S}(\text{O})\text{y-R}^{14}$, wherein R^{14} and y are as defined in 1.7.7,
 - 6. $-\text{NH}_2$,
 - 7. $-\text{O}-(\text{C}_1-\text{C}_{10})\text{-alkyl}$, wherein alkyl is mono- to penta- substituted by substituents independently chosen from
 - 7.1 phenyl, which is unsubstituted or mono- to penta- substituted by substituents independently chosen from halogen or $-\text{O}-(\text{C}_1-\text{C}_4)\text{-alkyl}$,
 - 7.2 halogen,
 - 7.3 $-\text{NH}_2$,
 - 7.4 $-\text{OH}$,
 - 7.5 $-\text{COOR}^{16}$, wherein R^{16} is hydrogen atom or $-(\text{C}_1-\text{C}_{10})\text{-alkyl}$,
 - 7.6 $-\text{NO}_2$,
 - 7.7 $-\text{S}(\text{O})\text{y-R}^{14}$, wherein y is zero, 1 or 2, R^{14} is $-(\text{C}_1-\text{C}_{10})\text{-alkyl}$, phenyl, which phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or $-\text{N}(\text{R}^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, phenyl, $-(C_1-C_{10})$ -alkyl, $-C(O)-(C_1-C_7)$ -alkyl, $-C(O)$ -phenyl, $-C(O)-NH-(C_1-C_7)$ -alkyl, $-C(O)-O$ -phenyl, $-C(O)-NH$ -phenyl, $-C(O)-O-(C_1-C_7)$ -alkyl, $-S(O)_y-R^{14}$, wherein R^{14} and y are defined as in 1.7.7, and wherein the R^{13} alkyl or phenyl groups in each case are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

7.8 $-O$ -phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,

7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, isoxazolidine, thiophene, 2-isoxazoline, isothiazolidine, 2-isothiazoline, or thiomorpholine,

7.10 $-(C_3-C_7)$ -cycloalkyl or

7.11 $=O$,

8. $-N(R^{17})_2$, wherein R^{17} is independently of one another chosen from hydrogen atom, phenyl, $-(C_1-C_{10})$ -alkyl, $-C(O)$ -phenyl, $-C(O)-NH-(C_1-C_7)$ -alkyl, $-C(O)-(C_1-C_{10})$ -alkyl, $-C(O)-O$ -phenyl, $-C(O)-NH$ -phenyl, $-C(O)-O-(C_1-C_7)$ -alkyl, $-S(O)_y-R^{14}$, wherein R^{14} and y are as defined as in 1.7.7,

and wherein alkyl or phenyl in each case are unsubstituted or mono- to penta-substituted independently of one another as defined under 1.7.1 to 1.7.11, or

R¹⁷ together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

9. -NH-C(O)-R¹⁵, wherein R¹⁵ is

- 9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine, wherein said radical is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, -CF₃, benzyl or by -(C₁-C₁₀)-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
- 9.2 -(C₁-C₁₀)-alkyl, wherein alkyl is mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 or by -O-(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
- 9.3 -(C₃-C₇)-cycloalkyl,
- 9.4 -N(R¹³)₂, wherein R¹³ is as defined in 1.7.7 provided that -N(R¹³)₂ is not -NH₂, or
- 9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, by -O-(C₁-C₁₀)-alkyl, by -CN, by -CF₃, by -(C₁-C₁₀)-alkyl, wherein alkyl is mono to tri- substituted by substituents

independently chosen from those as defined under 1.7.1 to 1.7.11, or
by two substituents of the phenyl radical which form a dioxolan ring,

10. $-C(O)-R^{12}$, wherein R^{12} is phenyl or $-(C_1-C_7)$ -alkyl, wherein phenyl or alkyl are mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
11. $-C(O)-O-R^{12}$, wherein R^{12} is phenyl or $-(C_1-C_7)$ -alkyl, wherein phenyl or alkyl are mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
12. $-O-(C_1-C_6)$ -alkyl- $O-(C_1-C_6)$ -alkyl,
13. $-O-(C_0-C_4)$ -alkyl- $-(C_3-C_7)$ -cycloalkyl or
14. $-(C_1-C_4)$ -alkyl- $N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7,

- R^5 is
1. a hydrogen atom,
 2. $-(C_1-C_{10})$ -alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.4,
 3. $-C(O)-R^9$, wherein R^9 is
 $-NH_2$, $-(C_1-C_{10})$ -alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.4, or $-N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7, or

4. $-S(O)_2-R^9$, wherein R^9 is as defined in 3 immediately above, or

R^4 and R^5 together with the atom to which they are bonded form a heterocycle, or

R^3 and R^5 together with the atom to which they are bonded form a heterocycle containing an additional oxygen atom in the ring and

R^6 , R^7 and R^8 independently of one another are chosen from hydrogen atom or methyl, or

in case b)

the substituents R^1 , R^2 and R^4 may be independently chosen as defined under 1.1 to 1.18 in case a) above,

- R^3 is
1. $-CF_3$,
 2. $-CF_2-CF_3$,
 3. $-CN$,
 4. $-COOH$,
 5. $-NO_2$,
 6. $-NH_2$,
 7. $-O-(C_1-C_{10})$ -alkyl, wherein alkyl is mono- to penta substituted by substituents independently chosen from
 - 7.1 phenyl, which is unsubstituted or mono- to penta- substituted by substituents independently chosen from halogen or $-O-(C_1-C_4)$ -alkyl,
 - 7.2 halogen,
 - 7.3 $-NH_2$,
 - 7.4 $-OH$,
 - 7.5 $-COOR^{16}$, wherein R^{16} is hydrogen atom or $-(C_1-C_{10})$ -alkyl,
 - 7.6 $-NO_2$,
 - 7.7 $-S(O)_y-R^{14}$, wherein y is zero, 1 or 2, R^{14} is $-(C_1-C_{10})$ -alkyl, phenyl, which phenyl is unsubstituted or mono- to penta- substituted by

substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or $-N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, phenyl, $-(C_1-C_{10})$ -alkyl, $-C(O)-(C_1-C_7)$ -alkyl, $-C(O)$ -phenyl, $-C(O)-NH-(C_1-C_7)$ -alkyl, $-C(O)-O$ -phenyl, $-C(O)-NH$ -phenyl, $-C(O)-O-(C_1-C_7)$ -alkyl, $-S(O)_y-R^{14}$, wherein R^{14} and y are defined as in 1.7.7, and wherein the R^{13} alkyl or phenyl groups in each case are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

7.8 $-O$ -phenyl, wherein phenyl is unsubstituted or mono- to penta- by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,

7.9 a radical selected from tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,

7.10 $-(C_3-C_7)$ -cycloalkyl or

7.11 $=O$,

8. $-N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7,

9. $-NH-C(O)-R^{15}$, wherein R^{15} is

9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine,

pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine, wherein said radical is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, -CF₃, benzyl or by -(C₁-C₁₀)-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,

- 9.2 -(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 or by -O-(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
- 9.3 -(C₃-C₇)-cycloalkyl,
- 9.4 -N(R¹³)₂, wherein R¹³ is as defined in 1.7.7, or
- 9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, by -O-(C₁-C₁₀)-alkyl, by -CN, by -CF₃, by -(C₁-C₁₀)-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or by two substituents of the phenyl radical which form a dioxolan ring,
- 10. -S(O)y-R¹⁴, wherein R¹⁴ and y are as defined in 1.7.7,
- 11. -C(O)-R¹², wherein R¹² is phenyl or -(C₁-C₇)-alkyl, wherein phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,

12. $-C(O)-O-R^{12}$, wherein R^{12} is phenyl or $-(C_1-C_7)$ -alkyl, wherein phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
13. $-(C_1-C_{10})$ -alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11,
14. $-O-(C_1-C_6)$ -alkyl- $O-(C_1-C_6)$ -alkyl,
15. $-O-(C_0-C_4)$ -alkyl- (C_3-C_7) -cycloalkyl or
16. $-(C_1-C_4)$ -alkyl- $N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7,

R^5 is as defined as R^5 in case a) above,

R^6 , R^7 and R^8 independently of one another are chosen from hydrogen atom or methyl, with the following provisos for case b):

when R^6 is methyl, R^3 is not an $O-(C_1-C_{10})$ -alkyl monosubstituted by either an unsubstituted phenyl or a $-COO-(C_1-C_{10})$ -alkyl; and


when R^3 is an $O-(C_1-C_{10})$ -alkyl monosubstituted by a $-(C^3-C^7)$ -cycloalkyl, R^6 is hydrogen.

68. (New) A method for the production of a pharmaceutical for the prophylaxis or therapy of disorders in whose course an increased activity of I $_{\kappa}$ B kinase is involved, comprising

bringing into a suitable administration form at least one compound chosen from a compound of formula II

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



or a stereoisomeric form of a compound of the formula II or a physiologically tolerable salt of a compound of the formula II, together with a pharmaceutically suitable and physiologically tolerable excipient, wherein;

R^1 and R^2 are independently of one another chosen from hydrogen atom,

halogen, cyano, amino, $-O-(C_1-C_4)$ -alkyl, nitro, $-CF_3$, $-CF_2-CF_3$,

$-S(O)_y-R^{14}$,

wherein y is 1 or 2, R^{14} is amino, $-(C_1-C_7)$ -alkyl or phenyl,

which phenyl is unsubstituted or mono- to tri-substituted as defined for substituents under 1.7.1 to 1.7.11 in claim 67,

$-N(R^{18})_2$, wherein R^{18} is independently of one another chosen from

hydrogen atom, $-(C_1-C_7)$ -alkyl- $C(O)-(C_1-C_7)$ -alkyl, $-C(O)$ -phenyl,

$C(O)$ -pyridyl, $-C(O)-NH-(C_1-C_4)$ -alkyl, $-C(O)-O$ -phenyl, $-C(O)-O-$

(C_1-C_4) -alkyl or $-(C_1-C_{10})$ -alkyl, wherein pyridyl, alkyl or phenyl

are unsubstituted or mono- to tri- substituted independently of

one another as defined under 1.7.1 to 1.7.11 in claim 67, or

R^{18} together with nitrogen atom to which it is bonded form

a heterocycle having 5 to 7 ring atoms,

R³ is cyano, amino, -O-(C₁-C₄)-alkyl, nitro, -CF₃, -CF₂-CF₃, -S(O)_y-R¹⁴, wherein y is 1 or 2, R¹⁴ is amino, -(C₁-C₇)-alkyl or phenyl, which phenyl is unsubstituted or mono- to tri-substituted as defined for substituents under 1.7.1 to 1.7.11 in claim 67, -N(R¹⁸)₂, wherein R¹⁸ is independently of one another chosen from hydrogen atom, -(C₁-C₇)-alkyl-C(O)-(C₁-C₇)-alkyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-O-phenyl, -C(O)-NH-(C₁-C₄)-alkyl, -C(O)-O-(C₁-C₄)-alkyl, or -(C₁-C₁₀)-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 in claim 67, or R¹⁸ together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms, and


R⁵ is hydrogen atom, -(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.4 in claim 67, -C(O)-R⁹ or -S(O)₂-R⁹, wherein

R⁹ is -(C₁-C₁₀)-alkyl, -O-(C₁-C₁₀)-alkyl, wherein alkyl is unsubstituted or mono- to tri- substituted independently of one another as defined under 1.7.1 to 1.7.4 in claim 67, or phenyl, which is unsubstituted or mono- to tri- substituted as defined under 1.7.1 to 1.7.11 in claim 67, or -N(R¹⁸)₂, wherein R¹⁸ is independently of one another chosen from hydrogen atom, -(C₁-C₇)-alkyl-C(O)-(C₁-C₇)-alkyl, -C(O)-phenyl, C(O)-pyridyl, -C(O)-NH-(C₁-C₄)-alkyl, -C(O)-O-phenyl, -C(O)-O-(C₁-C₄)-alkyl or -(C₁-C₁₀)-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri- substituted independently of one another as

defined under 1.7.1 in to 1.7.11 in claim 67, or R^{18} together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms.

69. (New) A method for the production of a pharmaceutical for the prophylaxis or therapy of disorders in whose course an increased activity of I_kB kinase is involved, comprising

bringing into a suitable administration form at least one compound chosen from a compound of formula II



or a stereoisomeric form of a compound of the formula II or a physiologically tolerable salt of a compound of the formula II, together with a pharmaceutically suitable and physiologically tolerable excipient, wherein;

R^1 is bromo, $-CF_3$ or chloro,

R^2 is hydrogen atom or $O-(C_1-C_2)$ -alkyl,

R^3 is $-N(R^{18})_2$, wherein R^{18} is independently of one another chosen from hydrogen atom, $-C(O)$ -pyridyl, $-C(O)$ -phenyl, $-(C_1-C_7)$ -alkyl, $-C(O)-(C_1-C_4)$ -alkyl or $-C(O)-O-(C_1-C_4)$ -alkyl, wherein alkyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from halogen or $-O-(C_1-C_2)$ -alkyl, and

R^5 is hydrogen atom, methyl or $-S(O)_2-CH_3$.